Novo Nordisk A/s

Other

Novo Nordick A/s

Henrik Bengtsson

Tinna Bjoerk Aradottir

Pete Brockmeier

Lars Eilertsen

Emil Gram Spork

Jan Harald Preuthun

Ole Christian Nielsen

Leif Johannsen

Vera Pinto Glenting

Steffen Hansen

Mads Schenstroem Stefansen

Bo Kvolsbjerg

Claus Schmidt Moller

Johannes Jan Struijk

Jonas Kildegaard Pedersen

Ronan Carroll

Brad Warren Van Orden

Jim Radmer

Erik Winkel Ethelfeld

Laurits Hoejgaard Olesen

Simon Rorvig

Thomas Dedenroth Miller

Christian Hoejris Nielsen

Jens Aage Munk

Claude Teisen-Simony

Jeppe Sturis

Brian Jensen

Ulla Ribel-Madsen

Bjorn Gullak Larsen

Philip Albert Sparholt

Thomas Bjarnsholt

Louise Wagner Petersen

Jakob Oest Wielandt

Bjørn Gullak Larsen

Søren Steenfeldt-Jensen

Rikke Bjerring Andersen

Per Einar Pontus Holm

Finn Jensen

Henning Gråskov

Henning Graaskov

Joern Drustrup

John Aasted Soerensen

Keld Baden-Kristensen

Morten Lind Jensen

Toke Folke Christensen

Louise Wagner Noergaard

Kezia Ann Friis Praestmark

Per Hvid Hansen

Soeren Steenfeldt-Jensen

Casper Bo Jensen

Frederik Kaae Kirk

Anders Dejgaard

Alan Moses

Leif Engmann Kristensen

Claus Moser

Christian Højris Nielsen

Nils Göran Marnfeldt

Terkel Valentin Thomsen

Kezia A Juul

Le Tommy

Nicola Levandis

Randloev Jette

Anders NØRBYGAARD

Mads Schenstrøm Stefansen

Jørn Drustrup

Tinna Bjórk ARADÓTTIR

Jonas Kildegård Pedersen

Tinna Björk ARADÓTTIR

A drug delivery system comprises an indicator element and a sensor system. The indicator element is arranged to rotate relative to a reference component and corresponding to a reference axis and comprises a plurality of dipole magnets. The sensor system comprises a plurality of magnetometers arranged non-rotational relative to the reference component and adapted to determine continuous magnetic field values from the plurality of dipole magnets, as well as processor means configured to determine on the basis of measured values from the plurality of magnetometers a rotational position and/or a rotational movement of the indicator element.

Drug delivery system with multipolar magnet and sensor system

A flow communication unit () for establishing flow communication from a multi-use drug delivery device adapted for extended use, to a flow conducting device, wherein the drug delivery device comprises a reservoir comprising multiple doses of a liquid drug formulation, wherein the reservoir is adapted to pressurize the liquid drug formulation, wherein the flow conducting device () is adapted for conducting the drug to the subcutaneous tissue of a subject, wherein the flow communication unit is adapted for being in an unconnected and a connected configuration, whereby the flow communication unit () is adapted to enable the extended use of the multi-use drug delivery device.

Flow communication unit with unconnected and connected configuration

Systems and methods are provided for adjusting long acting insulin medicament dosages for a subject. A plurality of timestamped glucose measurements of the subject is obtained. A titration glucose level () is computed as a measure of central tendency () of a titration subset of small glucose measurements () identified within the timestamped glucose measurements, wherein the measure of central tendency represents a measure of small glucose measurements for the primary time window. A long acting insulin medicament dosage () is adjusted or maintained based upon the obtained titration glucose level ().

Basal titration with adaptive target glucose level

A multi-use drug delivery device for extended use, wherein the multi-use drug delivery device comprising a multi-use main portion () and a single-use flow conducting device () adapted for conducting drug to the subcutaneous tissue of a subject, wherein the change from a connected configuration to an unconnected configuration of the main portion and the flow conducting device is through the intermediate configuration. The intermediate configuration comprises an equalizing channel defining an equalizing flow path () different from an unintended flow path (). The equalizing channel is adapted for equalizing the fluid pressure in a fluid communication volume () to the fluid pressure in the external environment, upon changing the configuration from the connected to the intermediate configuration and thereby expanding an internal volume, whereby an equalizing fluid flow along the equalizing flow path is larger than an unintended flow along the unintended flow path, whereby equalization of the fluid communication volume is provided with a reduced risk of introducing microorganisms from the flow channel () into the reservoir ().

Multi-use drug delivery device for drugs with less preservatives

Systems and methods are provided for optimizing short acting insulin medicament dosage timing relative to a meal event for a subject. Glucose measurements of the subject over a time course and the timing of the measurements are obtained. Meal events in the time course and information regarding when dosages were injected into the subject relative to the meal events is obtained. Bins, each for a different time range for when a dosage is injected relative to a meal event, are constructed. Each bin is assigned glucose measurements in one or more periods within the time course in which the subject injected the dosage within the time range associated with the bin. A glycaemic risk measure is determined for each bin with the assigned measurements and used to identify an optimal relative time range for the subject. This is communicated to a health care practitioner or to the subject.

Systems and methods for optimization of bolus timing relative to meal events

Systems and methods for evaluating insulin medicament dosage regimen adherence by a subject are provided. A description of metabolic events the subject engaged in is obtained. Each event comprises a timestamp and a classification that is one of insulin regimen adherent and insulin regimen nonadherent. Events are binned into consecutive time windows on the basis of time to obtain a plurality of subsets. Adherence values are computed. Each adherence value is for a subset and is computed by dividing the insulin regimen adherent events by the total number of events in the subset. Adherence values are combined into a composite value by a process that comprises downweighting a first adherence value, representing a first time window, with respect to a second adherence value, representing a second time window, when the first time window occurs in time before the second time window. The composite value is communicated as a single representation.

Systems and methods for analysis of insulin regimen adherence data

A subject is prescribed short and long acting insulin medicament regimens. When a qualified fasting event occurs, the basal insulin sensitivity estimate of the subject is updated using (i) an expected fasting blood glucose level based upon the long acting insulin medicament dosing specified by the long acting regimen during the fasting event, (ii) glucose measurements contemporaneous with the fasting event and (iii) a prior insulin sensitivity factor. A basal insulin sensitivity factor curve is calculated from the updated basal insulin sensitivity estimate. A bolus insulin sensitivity estimate of the subject is updated upon occurrence of a correction bolus with a short acting insulin medicament using (i) an expected blood glucose level based upon the correction bolus, (ii) glucose measurements after occurrence of the correction bolus, and (iii) a prior insulin sensitivity factor. A bolus insulin sensitivity factor curve is calculated from the updated bolus insulin sensitivity estimate.

Systems and methods for the determination of insulin sensitivity

The present invention provides a needle unit () for use with a pen injection device, wherein the needle unit () comprises a needle shield () and an axially movable needle hub ().

Needle unit with floating needle hub

Systems and methods are provided for adjusting a standing insulin medicament dosage regimen for a subject. Fasting events are identified using autonomous timestamped glucose measurements of the subject in a first data set. A second data set, from one or more insulin pens used to apply the standing regimen, comprises records, each record comprising a timestamped event specifying an amount of injected insulin medicament. Each fasting event is characterized as adherent or nonadherent. A fasting event is adherent when the second data set includes one or more records that temporally and quantitatively establish adherence with the standing regimen during the fasting event. Conversely, a fasting event is nonadherent when the second data set fails to temporally and quantitatively establish adherence with the standing regimen. Dosages in the standing regimen are adjusted using glucose measurements contemporaneous with adherent fasting events and by excluding glucose measurements contemporaneous with nonadherent fasting events.

Regimen adherence measure for insulin treatment based on glucose measurements and insulin pen data

Systems and methods are provided for adjusting a basal/bolus ratio in a standing insulin regimen for a subject that comprises daily amounts of basal and bolus insulin medicaments that define an initial basal/bolus ratio. A data set comprising glucose measurements of the subject with a respective timestamp for each such measurement over a time course is obtained. One or more fasting events are identified in the time course. A temporal glucose gradient is computed for each fasting event using the glucose measurements in the data set within the fasting event time period. Fasting event glucose gradients are used to determine whether to recommend adjustment to the basal/bolus ratio for the subject without change to the daily total insulin medicament. The recommended adjustment to the basal/bolus ratio is communicated when the determination is made to make the recommended adjustment to the basal/bolus ratio for the subject.

Systems and methods for adjusting a basal/bolus ratio in an insulin regimen

An assembly includes a sealed drug reservoir unit, a subcutaneous flow conducting device in the form of a needle unit or an infusion set, and a flow communication unit. The flow communication unit includes a proximal hollow needle adapted to penetrate a needle-penetrable septum of the reservoir, a first flow-way inflow communication with the proximal needle and comprising a pressure-controlled valve, a second flow-way in flow communication with the first flow-way, an amount of preservative arranged to react with a substance received by the second flow-way, and distal flow communication structure adapted to provide flow communication between the second flow-way and the needle unit. The valve is controlled to open when the reservoir is pressurized, the preservative being provided to react with substances introduced to the second flow way via the needle unit.

Flow communication unit with preservative

Systems and methods are provided for adjusting long acting insulin medicament dosages for a subject. A plurality of timestamped glucose measurements of the subject and insulin injection data is obtained. A first glycaemic risk measures is determined, where the first risk glycaemic risk measure is i) glucose level variability across the glucose measurements, (ii) a variability in fasting glucose levels calculated from the glucose measurements, (iii) a minimum observed glucose measurement in the plurality of glucose measurements (iv) rate of change in ISF, or (v) adherence values. A fasting blood glucose target function is computed based upon at least the first glycaemic risk measure thereby obtaining an updated target fasting blood glucose level that is between a minimum and maximum target fasting blood glucose level. The long acting insulin medicament dosage is adjusted based upon the updated target fasting blood glucose level.

A device () for estimating the risk of a future hypoglycemic event for a subject with a standing insulin regimen (), wherein the standing insulin regimen comprises one or more types of insulin medicament dosage regimen (), wherein each of the one or more types of insulin medicament dosage regimen () comprises a type of insulin medicament () defining one or more types of insulin medicaments. Using the evaluation of a glucose concentration, a first time derivative and an insulin on board for the subject in a current metabolic state, and the evaluation of a glucose concentration, a first derivative and a historical insulin on board to estimate a hypoglycemic risk measure.

Systems and methods for estimating the risk of a future hypoglycemic event

Growing community of inventors

Taastrup, Denmark

Henrik Bengtsson